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Introduction: Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or
phosphatase and tensin homolog (PTEN) loss) has been shown to enhance breast cancer cell survival and confer
resistance to chemotherapeutic agents. We studied the prognostic and predictive value of PIK3CA mutations and
PTEN low in patients receiving paclitaxel alone or in combination with lapatinib.
Methods: Immunohistochemistry and mutation analyses were used to evaluate PTEN and PIK3CA, respectively.
Kaplan-Meier analysis with log-rank tests, logistic regression and Cox models were used in analyses of these
biomarkers with efficacy endpoints.
Results: In the overall population, PIK3CA mutations were associated with poorer overall survival (OS) (hazard
ratio (HR) = 1.87; 95% confidence interval (CI): 1.22, 2.88; P = 0.001). PTEN expression was not associated with OS
(P = 0.474). In the PIK3CA wild-type subgroup, lapatinib plus paclitaxel reduced risk of progression compared
with paclitaxel alone (HR = 0.44; 95% CI: 0.28, 0.69; P <0.0001); progression-free survival (PFS) was not significantly
improved within the PIK3CA mutation subgroup (P = 0.179). In the PTEN low group, OS was improved with
addition of lapatinib (P = 0.039). In both PTEN subgroups, addition of lapatinib was associated with improvements
in PFS (P <0.050). PIK3CA and PTEN were not predictive of treatment based on interaction tests (P >0.05).
Conclusions: PTEN was neither a significant prognostic nor predictive factor. PIK3CA mutations were an adverse
prognostic factor for survival but not predictive for lapatinib benefit.
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Deregulation of the phosphatidylinositol 3-kinase (PI3K)
pathway is frequently observed in many human cancers,
and as a consequence is implicated in cancer patho-
physiology. In breast cancer, gain-of-function mutations
in the PI3K catalytic subunit alpha gene (PIK3CA) and
loss of phosphatase and tensin homolog (PTEN) func-
tion are common genomic events, either of which can
result in an activated PI3K pathway phenotype and in-
duction of oncogenic transformation, as demonstrated in
preclinical models [1-5]. These aberrations have been
shown to be associated with clinicopathological charac-
teristics including histological subtype, tumor grade,
hormone receptor status and human epidermal growth
factor receptor 2 (HER2) expression [5-7]. Additionally,
studies have reported PIK3CA and PTEN as prognostic
indicators and effectors of response to chemotherapies,
endocrine therapy and HER2-directed therapies, (that is,
trastuzumab and lapatinib) [2,5,6,8-14]. The clinical rele-
vance of PI3K pathway deregulation should be evaluated
in the context of breast cancer molecular subtypes as
these subtypes differ in survival outcome, treatment
response, and frequency of PIK3CA mutations and PTEN
loss [6,15-18].
In breast cancers driven by HER2 the frequency of
PIK3CA mutations or PTEN loss has been described as
up to 40% [19]. The functional consequences of breast
cancers harboring alterations in both HER2 and the
PI3K pathway are most likely to provide a selective
advantage in cellular processes that include cell growth
and survival. More importantly, elucidating the impact
PIK3CA mutations and/or PTEN loss have on the effi-
cacy of HER2-directed agents is essential to the advance-
ment of personalized medicine and the development of
rational targeted therapy combinations with the aim to
improve patient outcome.
Lapatinib, an orally administered, small molecule,
reversible inhibitor of the intracellular tyrosine kinase
domain of HER2, is currently approved for the treatment
of HER2-positive metastatic breast cancer in combination
with chemotherapy or aromatase therapy in postmeno-
pausal women with hormone receptor-positive disease
[20]. The effects of PIK3CA mutations and/or PTEN loss
on the efficacy of lapatinib have been evaluated in
preclinical and clinical studies. Evidence from one study
evaluating the efficacy of lapatinib and trastuzumab in 18
HER2-amplified cell lines indicated that PI3K pathway
activation correlated with trastuzumab resistance yet did
not confer resistance to lapatinib in all cell line models,
and that lapatinib activity was independent of these
molecular features [21]. This finding was confirmed in
clinical studies in patients with HER2-positive breast
cancer, whereby PIK3CA mutations and PTEN loss were
not significantly associated with lapatinib efficacy [22-25].In contrast, other studies have reported that PTEN
loss of function and PIK3CA mutations adversely im-
pact lapatinib efficacy [9,13]. Although results from
several studies suggest the efficacy of lapatinib is inde-
pendent of PIK3CA and PTEN, overall, the findings across
studies are inconsistent.
We conducted exploratory analyses on the prognostic
and predictive value of PI3K pathway activation in a
large cohort of patients with HER2-positive metastatic
breast cancer who received paclitaxel in combination with
lapatinib or placebo in the randomized, Phase III study,
EGF104535 (NCT00281658). We focused the analysis on
PTEN protein expression as a measure of PTEN loss of
function (PTEN low) and on three mutation hotspot
regions in the PIK3CA gene (E542K and E545K/D in
exon 9, which encodes the helical domain; H1047R in
exon 20, which encodes the kinase domain), as these mu-
tations are well characterized as constitutively activating
and oncogenic.
Methods
Patient population and study design
The eligibility criteria and study design for EGF104535
have been previously reported [26]. Briefly, 444 patients
from Brazil, China, Hong Kong, Pakistan, Peru, Russia,
Thailand, and Ukraine with HER2 gene-amplified meta-
static breast cancer, and who had not received prior ther-
apy for metastatic disease, were stratified by hormone
receptor status (estrogen receptor (ER)-negative and pro-
gesterone receptor (PgR)-negative vs. ER-positive and /or
PgR-positive) and metastatic disease status (nonvisceral
vs. visceral) then randomly assigned in a 1:1 ratio to
receive first-line treatment with paclitaxel (80 mg/m2
weekly for three weeks of a four-week cycle) plus lapa-
tinib (1500 mg once daily, continuously) or paclitaxel
(80 mg/m2 weekly for three weeks of a four-week cycle)
plus placebo (once daily, continuously).
The study (EGF104535) was performed in accordance
with the Declaration of Helsinki and approved by local
ethics committees, details of which have been previously
reported [26]. All patients provided written informed con-
sent to take part in the study. Additional consent was
provided by patients who took part in the tumor genetics
analysis.
Specimen characteristics
Baseline tissue from primary breast tumor or metastatic
site was obtained in the form of formalin-fixed, paraffin-
embedded (FFPE) material (slides or blocks).
Assay methods
Immunohistochemistry (IHC) staining using a rabbit
monoclonal antibody against PTEN (138G6; Cell Signal-
ing Technology, Danvers, MA, USA) in an analytically
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tein expression on FFPE whole tissue sections. Single
pathology review (that is, two pathologists participated
in the study; each case was reviewed by one pathologist)
and image analysis were performed, thereby producing
an ordinal score and optical density score, respectively.
Staining intensity was allocated a score of 0, 1+, 2+,
or 3 + .
Two approaches to PTEN analysis were considered
based on the presence of cytoplasmic staining in invasive
tumor cells. The primary analysis considered tumors
scored IHC 0/1+ as having PTEN low. The secondary
analysis considered tumors scored IHC 0 as exhibiting
an absence of PTEN expression whereas those scored
IHC 1+, 2+, or 3+ were considered as exhibiting any
PTEN expression. PTEN immunoreactivity in the sur-
rounding stroma acted as the internal positive control, a
method consistent with that previously reported [12].
PIK3CA mutation test kit (Qiagen/DxS, Germantown,
MD, USA) was used to assess mutation status on genomic
deoxyribonucleic acid (DNA) isolated from FFPE tumor
tissue. The assay detects exon 9 mutations E542K and
E545D/K, and the exon 20 mutation H1047R. The pres-
ence of any one of the four PIK3CA mutations in a tumor
was designated as PIK3CA mutation, whereas the absence
of these four mutations was designated as PIK3CA
wild-type.
A tumor was defined as having PI3K pathway activa-
tion if there was PTEN low, or a PIK3CA mutation or
both.
Study objective
The primary objective of this analysis was to evaluate the
predictive and prognostic value of PIK3CA mutations
and/or PTEN low in HER2-positive patients receiving
first-line treatment with paclitaxel alone or in combin-
ation with lapatinib. The effect of PTEN low, PIK3CA
mutation and PI3K pathway activation (PTEN low and/or
PIK3CA mutation) was assessed in relevant clinical end-
points (overall survival (OS), progression-free survival
(PFS), overall response rate (ORR), and clinical benefit
rate (CBR)).
Statistical analyses
The efficacy analyses were conducted on the intent-to-
treat (ITT) population which comprised all randomized
patients with available biomarker data.
The effect of PTEN low, PTEN any expression, PIK3CA
mutation, and PI3K pathway activation on OS and PFS
was assessed using a Cox proportional hazard model
including the marker as a covariate. Multivariate Cox
models adjusting for two stratification factors (hormo-
nal status (hormone receptor-negative vs. hormone
receptor-positive) and metastatic sites of disease (visceralvs. nonvisceral)) were performed to assess the interaction
between treatment and the biomarker. The Wald chi-
square test was used to test for the interaction. Kaplan-
Meier survival curves were generated by biomarker status
and treatment group; a log-rank test was used in the com-
parison between treatment arms. Association between
PTEN low, PTEN any expression, PIK3CA mutation,
PI3K pathway activation, and ORR and CBR was assessed
using logistic regression models for each separately.
For ORR, patients were divided into responder (complete
response (CR), partial response (PR)), and non-responder
groups (progressive disease (PD) or stable disease (SD)).
For CBR, patients were divided into clinical benefit
(CR, PR, or SD ≥24 weeks) and nonclinical benefit
(SD <24 weeks, PD) groups. Unknown responses were
excluded as these were exploratory analyses.
All tests comparing PIK3CA and PTEN with efficacy
endpoints were two-tailed and P ≤0.05 was considered
significant. The P values from these comparisons were
not adjusted for multiple comparisons.
Results
Baseline patient and tumor characteristics of the ITT
population for study EGF104535 are shown in Table 1.
Of the total study population, 390 patients had tissue
available for biomarker analyses and 274 of these pa-
tients provided written informed consent for optional
tumor genetics (that is, PIK3CA analysis). Of the 390
patient cases, 338 were from the primary tumor site
(86.7%), 37 from a metastatic site (9.5%), and the site was
not specified in 15 patient cases (3.8%); in the population
who gave consent for PIK3CA analysis, the overall per-
centages were consistent with the population with tissue
evaluable for biomarker analyses (specimen site out of 274
patient cases, 270 were primary (87.6%), 26 were meta-
static (9.5%), and 8 were not specified (2.9%)).
Evaluable results for PTEN and PIK3CA were available
for 91% (355/390) and 77% (210/274) of patients with
available tumor tissue and who provided consent for
tumor genetics, respectively. In the cohort of patients
with available tumor tissue and who provided consent,
24% (65/274) had tumors harboring PIK3CA mutations
(E542K, E545K/D, and H1047R); 13% (49/390) of pa-
tients with available tumor tissue had absence of PTEN
expression and 53% (205/390) had low PTEN expression.
Results for PTEN expression and PIK3CA mutation
analysis are summarized in Table 2. PTEN IHC staining
representative of the four IHC scores are presented in
Figure 1.
Effect of PIK3CA mutations and PTEN low on survival
outcome
In the overall study population, regardless of treatment,
the presence of PIK3CA mutations was associated with
Table 2 Summary of PTEN and PIK3CA results





tumor tissue, n (%)




PTEN IHC 0 28 (16) 21 (12)
PTEN IHC 1+ 76 (42) 80 (46)
PTEN IHC 0/1+ 104 (58) 101 (58)







PIK3CA mutation 29 (28) 36 (34)
PIK3CA wild-type 58 (56) 48 (45)
PIK3CA
indeterminate
17 (16) 22 (21)
Tumors with PTEN IHC
0/1+ and/or PIK3CA
mutationsc,d, n (%)
119/180 (66) 117/175 (67)
Tumors with PTEN IHC
0/1+ and PIK3CA
mutation, n (%)
14/104 (13) 20/106 (19)
aNonevaluable findings were due to factors such as insufficient tumor tissue,
absence of PTEN staining in stroma and poor DNA quality (PIK3CA). bSomatic
mutation analysis was optional. cPIK3CA mutation frequency: 65% (42/65) were
H1047R (35 cases are from primary tumor; 5 from metastatic; 2 from unknown
site); 25% were E545K/D (14 cases are from primary tumor; 1 from metastatic, 1
from unknown site); 11% were E542K (7 from primary tumor). dDefined as PI3K
pathway activation. DNA, deoxyribonucleic acid; IHC, immunohistochemistry;
PIK3CA, phosphatidylinositol 3-kinase subunit alpha gene; PTEN, phosphatase
and tensin homolog.
Table 1 Baseline patient and tumor characteristics (ITT
population)






50.0 (25-74) 50.5 (26-73)
Race, n (%)
Asian 192 (86) 192 (86)
Other 30 (14) 30 (14)
ECOG performance
status, n (%)
0 103 (46) 113 (51)
1 119 (54) 109 (49)
Central HER2
FISH + a, n (%)




111 (50) 113 (51)
Any visceral disease,
n (%)
187 (84) 186 (84)





Any therapy 171 (77) 182 (82)
Chemotherapy 160 (72) 173 (78)
Adjuvant 146 (66) 161 (73)
Hormonal therapy 53 (24) 44 (20)
Biologic 0 4 (2)
Radiotherapy 94 (42) 85 (38)
aFive cases were HER2 FISH-borderline: three from lapatinib + paclitaxel, two
from placebo + paclitaxel; two additional cases from placebo + paclitaxel never
FISH-tested. bA total of 12% of the study population had Stage IV breast
cancer at initial disease presentation (14% in lapatinib + paclitaxel; 11% in
placebo + paclitaxel). ECOG, Eastern Cooperative Oncology Group; FISH,
fluorescence in situ hybridization; HER2, human epidermal growth factor receptor
2; ITT, intent-to-treat.
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confidence interval (CI): 1.22, 2.88; P = 0.001; Figure 2a),
whereas PTEN expression was not associated with survival
in this population (P = 0.474; Figure 2b). PI3K path-
way activation, as defined by PTEN low and/or PIK3CA
mutation, was not associated with OS (P = 0.085, data
not shown).
PIK3CA mutations were significantly associated with
poorer survival in the paclitaxel plus placebo population
(P = 0.018, data not shown), whereas no statistically
significant association between PIK3CA mutation and
poorer survival was observed in the lapatinib plus pacli-
taxel population (P = 0.056, data not shown). PTEN low
and PI3K pathway activation were not significantly as-
sociated with survival in either individual treatment
arm (P >0.050, data not shown).Effect of PIK3CA mutations and PTEN low on lapatinib
efficacy
In the PIK3CA wild-type subgroup, treatment with
lapatinib plus paclitaxel reduced the risk of progression
compared with paclitaxel alone (n = 106; HR = 0.44; 95%
CI: 0.28, 0.69; P <0.0001); OS was not significant
(P = 0.732) (Figure 3). Addition of lapatinib was also
associated with significant improvement in ORR (P = 0.034)
(Figure 4). CBR was numerically higher in patients treated
with lapatinib-based therapy; however, the treatment dif-
ference was not significant (Figure 5).
In the PIK3CA mutation subgroup, a trend in a PFS
benefit was shown in the lapatinib plus paclitaxel sub-
group (HR = 0.71; 95% CI: 0.43, 1.17; P = 0.179); whereas,
OS, ORR, and CBR were not significantly different between
treatment groups (P >0.050) (Figures 3, 4 and 5).
OS was significantly improved in the PTEN low
subgroup with addition of lapatinib (P = 0.039) (Figure 3),
whereas OS was not significantly improved in the
subgroup without PTEN low. Addition of lapatinib was
associated with significant improvements in PFS, ORR,
PTEN IHC 0 PTEN IHC 1
PTEN IHC 3PTEN IHC 2
Figure 1 Representative PTEN IHC staining. Arrows point to stromal cells with positive PTEN staining. IHC, immunohistochemistry; PTEN,
phosphatase and tensin homolog.
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PTEN subgroups (low/expression expression) (P <0.050)
(Figures 3, 4 and 5).
PI3K pathway activation was associated with a signifi-
cant improvement in PFS and OS with the addition of
lapatinib to paclitaxel (P <0.0001; P = 0.013, respectively).
In this same subgroup, significant improvements in
ORR and CBR (P ≤0.002) were also observed in patients
receiving lapatinib compared with paclitaxel alone
(Figures 4 and 5).
Predictive effect of PIK3CA mutations and PTEN low on
lapatinib
In a multivariate analysis after adjusting for stratification
factors, the interaction effect between PIK3CA and
treatment in OS was not significant (P = 0.809); inter-
action effect in PFS was also not significant (P = 0.095).
The interaction effect of PTEN low with treatment in
OS and PFS was not significant (P = 0.088; P = 0.219,
respectively) (Tables 3 and 4.)
Discussion
The effect of PIK3CA mutations and PTEN loss as prog-
nostic factors has been evaluated extensively in breast
cancer. However, in earlier studies these markers were
evaluated in the absence of considering survival differencesin breast cancer molecular subtypes. Additionally, the
frequency at which these genetic alterations occur varies
according to molecular subtype [19].
To the best of our knowledge, the present study is the
largest of its kind evaluating the prognostic and predict-
ive value of PIK3CA mutations and PTEN expression in
patients with HER2-amplified metastatic breast cancer
treated with lapatinib-based therapy. Overall, the preva-
lence of PIK3CA mutations and PTEN low was 31% and
58%, respectively, which is within the range of reported
frequencies in HER2-positive breast cancer [14,19,27-31].
In the overall study population, and in patients in the pac-
litaxel plus placebo group, PIK3CA mutations were an
adverse prognostic factor for survival, whereas in patients
treated with paclitaxel plus lapatinib PIK3CA mutations
were not significantly associated with OS outcome. In
contrast, neither PTEN low alone nor when PIK3CA
mutation and PTEN low were considered together
were significantly associated with survival in any of the
populations studied.
In a study that evaluated the association of PIK3CA
status with clinicopathological factors in primary breast
cancer, the effect of PIK3CA mutations was analyzed
within molecular subtypes. In the overall population, as
well as in the HER2-positive subtype, PIK3CA mutations
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Figure 2 OS outcome by: (a) PIK3CA mutation status; and (b) PTEN low. OS, overall survival; PIK3CA, phosphatidylinositol 3-kinase subunit
alpha gene; PTEN, phosphatase and tensin homolog.
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PTEN low (n = 205)
Without PTEN expression (n = 49)
PTEN expression (n = 306)
PIK3CA wild-type (n = 106)
PIK3CA mutation (n = 65)
Without PI3K pathway activation (n = 46)
PI3K pathway activation (n = 236)
Favors Lap + Pac Favors Pbo + Pac
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2
HR
PFS
ITT population (n = 444)
Without PTEN low (n = 150)
PTEN low (n = 205)
Without PTEN expression (n = 49)
PTEN expression (n = 306)
PIK3CA wild-type (n = 106)
PIK3CA mutation (n = 65)
Without PI3K pathway activation (n = 46)
PI3K pathway activation (n = 236)
Favors Lap + Pac Favors Pbo + Pac
Figure 3 Effect of PTEN and PIK3CA status on OS and PFS. Groups in red text = statistical significance of P <0.050. HR, hazard ratio; ITT, intent-
to-treat; OS, overall survival; PFS, progression-free survival; PI3K, phosphatidylinositol 3-kinase; PIK3CA, PI3K subunit alpha gene; PTEN, phosphatase
and tensin homolog. PTEN low, IHC 1+/0; PTEN expression, IHC3+/2+/1+; PI3K pathway activation, PTEN low and/or PIK3CA mutation.






































































































OR (95% CI): 2.47 (1.37, 4.49)
P = .002
OR (95% CI): 2.41 (1.42, 4.12)
P = .0007
OR (95% CI): 2.78 (1.07, 7.57)
P = .034
OR (95% CI): 2.42 (1.28, 4.63)
P = .005
OR (95% CI): 2.21 (1.04, 4.82)
P = .040
Figure 4 Effect of PIK3CA and PTEN status on ORR. CI, confidence interval; IHC immunohistochemistry; ORR, overall response rate; OR, odds
ratio; PI3K, phosphatidylinositol 3-kinase; PIK3CA, PI3K subunit alpha gene; PTEN, phosphatase and tensin homolog; PTEN low, IHC 1+/0; PTEN
expression, IHC3+/2+/1+; PI3K pathway activation, PTEN low and/or PIK3CA mutation.
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ceived a HER2-directed agent as part of their adjuvant
treatment [6]. Whereas in a study of 240 patients with
early-stage HER2-positive breast cancer treated with
adjuvant trastuzumab-based therapy, PIK3CA mutation-
positive breast cancer was associated with significantly
poorer OS. Furthermore, no significant association was
observed with low PTEN and OS or invasive disease-
free survival (DFS) [29]. The lack of a significant effect
of PTEN low on DFS within a treatment regimen was
further observed in the North Central Cancer Treatment
Group N9831 Intergroup clinical trial that was a Phase
III, randomized, three-arm study of adjuvant trastuzu-
mab in HER2-positive early-stage breast cancer. In this
study of over 3,500 patients, 1,802 patient cases were
evaluable for PTEN expression analysis by IHC. Regard-
less of treatment arm, one of which included patients
not treated with trastuzumab, low or absence of PTEN
expression did not adversely affect DFS outcome [14];
moreover, the benefit of adding trastuzumab to an adju-
vant chemotherapy regimen was observed in patients
regardless of PTEN status.
In another single-center study of 137 patients with
HER2-positive metastatic breast cancer treated with tras-
tuzumab, a slight trend toward shorter OS in the sub-
group of patients with PIK3CA mutations was observed,yet PTEN loss was associated with a significantly shorter
survival time. Consistent with the previously mentioned
study that evaluated the combined effect of PTEN low
and PIK3CA mutations to define PI3K pathway activation
[29], PI3K pathway activation was also significantly associ-
ated with shorter OS [27].
Further evidence of the adverse prognostic effect of
PIK3CA mutations in HER2-positive breast cancer was
provided in a large randomized Phase III study of patients
receiving docetaxel in combination with trastuzumab plus
placebo or docetaxel in combination with trastuzumab
plus pertuzumab. In this study, PFS was poorer in patients
with PIK3CA mutation-positive disease compared with
those with PIK3CA wild-type disease, independent of
treatment [31].
In our study, PIK3CA mutations and PTEN low were
not predictive of lapatinib efficacy as there was no signifi-
cant interaction effect with each marker and treatment.
However, the study is limited as it was a retrospective ana-
lysis and the number of patients with a PIK3CA mutation
was small. Furthermore, the study was not powered to
detect a statistically significant interaction. PTEN expres-
sion may not be predictive as both low and expression
subgroups derived significant benefit with lapatinib
and paclitaxel. Nevertheless, in three smaller clinical



































































































OR (95% CI): 3.15 (1.66, 6.12)
P = .0002
OR (95% CI): 3.05 (1.74, 5.46)
P < .0001
OR (95% CI): 3.15 (1.58, 6.49)
P = .0007




Figure 5 Effect of PIK3CA and PTEN status on CBR. CBR, clinical benefit rate; CI, confidence interval; IHC, immunohistochemistry; OR, odds
ratio; PI3K, phosphatidylinositol 3-kinase; PIK3CA, PI3K subunit alpha gene; PTEN, phosphatase and tensin homolog; PTEN low, IHC 1+/0; PTEN
expression, IHC3+/2+/1+; PI3K pathway activation, PTEN low and/or PIK3CA mutation.
Table 3 Summary of Cox regression model for OS with
treatment, PIK3CA mutation, PTEN low, and interaction
adjusting for stratification factors
Covariate HR (95% CI) Two-sided
P value
PIK3CA mutationa
Treatment (Lap + Pac/Pbo + Pac) (n = 171) 0.88 (0.53, 1.46) 0.611
HR status (negative/positive) 0.82 (0.55, 1.23) 0.343
Metastatic sites (visceral/nonvisceral only) 0.52 (0.30, 0.92) 0.024
PIK3CA mutation (yes/no) 2.24 (1.29, 3.88) 0.004
Treatmenta PIK3CA interaction 0.91 (0.41, 2.02) 0.809
PTEN low
Treatment (Lap + Pac/Pbo + Pac) (n = 355) 1.00 (0.67, 1.50) 0.998
HR status (negative/positive) 1.17 (0.89, 1.53) 0.256
Metastatic sites (visceral/nonvisceral only) 0.50 (0.33, 0.76) 0.001
PTEN low (yes/no) 1.16 (0.80, 1.69) 0.425
Treatmenta PTEN low interaction 0.62 (0.36, 1.07) 0.088
aPatients with a PIK3CA indeterminate tumor status were excluded. CI,
confidence interval; HR, hazard ratio; Lap, lapatinib; OS, overall survival; Pac,
paclitaxel; Pbo, placebo; PIK3CA, phosphatidylinositol 3-kinase subunit alpha
gene; PTEN, phosphatase and tensin homolog.
Table 4 Summary of Cox regression model for PFS with
treatment, PIK3CA mutation, PTEN low, and interaction
adjusting for stratification factors
Covariate HR (95% CI) Two-sided
P value
PIK3CA mutationa
Treatment (Lap + Pac/Pbo + Pac) (n = 171) 0.41 (0.27, 0.62) <0.0001
HR status (negative/positive) 0.86 (0.62, 1.20) 0.379
Metastatic sites (visceral/nonvisceral only) 0.77 (0.50, 1.17) 0.218
PIK3CA mutation (yes/no) 1.31 (0.84, 2.07) 0.238
Treatmenta PIK3CA interaction 1.76 (0.91, 3.43) 0.095
PTEN low
Treatment (Lap + Pac/Pbo + Pac) (n = 355) 0.59 (0.42, 0.83) 0.003
HR status (negative/positive) 1.01 (0.81, 1.26) 0.948
Metastatic sites (visceral/nonvisceral only) 0.66 (0.48, 0.89) 0.007
PTEN low (yes/no) 1.10 (0.81, 1.52) 0.537
Treatmenta PTEN low interaction 0.75 (0.48, 1.18) 0.219
aPatients with a PIK3CA indeterminate tumor status were excluded. CI,
confidence interval; HR, hazard ratio; Lap, lapatinib; Pac, paclitaxel; Pbo,
placebo; PIK3CA, phosphatidylinositol 3-kinase subunit alpha gene; PTEN,
phosphatase and tensin homolog.
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efficacy of lapatinib, whether administered alone or in
combination with chemotherapy [22-24]. A composite
definition of PI3K pathway activation to include known
aberrations that are proven to result in the activation of
this pathway may have greater predictive effect than the
individual factors alone. We analyzed the treatment effect
within a subgroup that included PIK3CA mutations
and PTEN low combined, and a statistically significant
improvement in OS and PFS with the combination of
lapatinib plus paclitaxel was observed; however, we did
not directly evaluate PI3K pathway activation in this pa-
tient cohort. Our findings are in contrast to a small study
(n = 57) of patients with HER2-positive metastatic breast
cancer where PI3K pathway activation, defined as PIK3CA
mutation and/or PTEN expression loss, resulted in lower
CBR in patients treated with lapatinib in combination with
capecitabine [13].
The inconsistencies across studies may be explained
by the methodological differences used in the determin-
ation of PTEN and PIK3CA. The IHC assays used in the
determination of PTEN protein expression across the
breast cancer studies were not standardized; the studies
reporting on the frequency of PTEN loss of expression
in breast cancer varied with the use of PTEN antibody,
scoring method, and definition of PTEN loss (that is,
PTEN low expression versus absence of PTEN expression).
Furthermore, the methods used in PIK3CA mutation ana-
lysis also varied in parameters that included sensitivity as
well as which mutations were evaluated. As evident in
these studies, methods that have undergone standardized
validation are essential to accurately determine PTEN and
PIK3CA status based on the consequential role these
markers could play in aiding therapeutic decisions.
The relevance of PIK3CA mutations and PTEN low
on the efficacy of HER2-directed agents has been evalu-
ated in many patient cohorts as the presence of these
alterations are implicated in resistance to trastuzumab
and lapatinib [8,9]. In our study, the efficacy results
were consistent with the addition of lapatinib to pacli-
taxel conferring treatment benefit in patients with HER-
positive metastatic breast cancer regardless of PIK3CA
status and PTEN expression.
Conclusions
Overall, PIK3CA mutations and PTEN low are not con-
clusively established as conferring resistance to lapatinib
in patient-based studies. Prospective studies that are
sufficiently powered to evaluate the interaction effect of
PIK3CA mutations and/or PTEN low on HER2-directed
therapies and thus provide the level of evidence required
to establish their clinical relevance may be needed for
future combination strategies with agents that target the
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